FDA approves Tesaro's ovarian cancer drug
(Reuters) - The U.S. Food and Drug Administration on Monday approved Tesaro Incâ€™s drug, niraparib, for the treatment of recurrent ovarian cancer.
Epithelial ovarian, fallopian tube or primary peritoneal cancer affects the tissue covering the ovary or lining of the fallopian tube or abdominal wall.